- Twist Bioscience ( NASDAQ: TWST ) and Illumina ( NASDAQ: ILMN ) will partner to expand customer access to the Illumina Exome 2.0 Plus panel to promote disease research.
- Terms call for Twist ( TWST ) to manufacture the Exome 2.0 Plus panel, which will be sold by Illumina ( ILMN ) under both companies' brands.
- Illumina ( ILMN ) will offer the panel with its DNA library preparation reagents as a library prep kit and exome enrichment solution for research applications.
- Seeking Alpha's Quant Rating views Illumina ( ILMN ) as a hold with high marks for profitability and momentum .
For further details see:
Twist, Illumina in partnership to expand access to genetic sequencing panel